What type of respiratory drugs does ensifentrine-Ohtuvayre belong to?

Ensifentrine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre is a new type of small molecule drug that is a PDE3 and PDE4 inhibitor. These two enzymes play a key role in the treatment of respiratory system diseases. PDE3 enzyme mainly hydrolyzes cyclic adenosine monophosphate (cAMP) and also has the ability to hydrolyze cyclic guanosine monophosphate (cGMP). PDE4 enzyme specifically hydrolyzes cAMP. By inhibiting these enzymes, exefentine can effectively increase intracellular levels of cAMP and/or cGMP, thereby producing a series of physiological effects in the respiratory system.

As a dualPDE3 and PDE4 inhibitor, exefentine can not only dilate the bronchi and relieve respiratory tract stenosis caused by COPD, etc. through this mechanism, but also reduce airway inflammatory response, relieve symptoms, and improve lung function. Due to its unique mechanism of action, ensefentin has shown significant efficacy in the treatment of chronic obstructive pulmonary disease (COPD), especially in improving respiratory function, alleviating cough and dyspnea, and is more effective than simple PDE3 inhibitors or PDE4 inhibitors.

From the perspective of drug type, ensefentin is a combined-acting respiratory drug that can act on two key biological pathways at the same time. Therefore, it not only has a bronchodilator effect, but also has an anti-inflammatory effect, giving it unique advantages in the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory diseases. The innovation in its therapeutic mechanism makes it a drug with potential, especially in treating patients for whom conventional treatments are ineffective.

Overall, the mechanism of action and indications of exefantine make it a very potential respiratory drug, especially for those COPD patients who are in urgent need of improving respiratory function and alleviating symptoms.The use of exefantine undoubtedly brings them new treatment hope.

Keyword tags: Ensifentrine, Ensifentrine, Ohtuvayre, PDE3, PDE4, dual action, respiratory drugs, chronic obstructive pulmonary disease, COPD, drug mechanism

References:https://www.drugs.com/ohtuvayre.html